~MILV .0625 News...
Nature's Bioceuticals is Ready to Battle the Common Cold and Flu
Oct 27, 2011 11:00:00 AM
CAPE CORAL, Fla., Oct. 27, 2011 /PRNewswire/ -- Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. (MILV.pk) announced that it has reached an agreement with the inventor of a spectacular cold and flu medicine that has been in development for many years.
The common cold, an infection of the upper respiratory tract, is caused by any of 200 different viruses. The viral infection and the immune system's battle against it produce the all-too-familiar symptoms: sore throat, nasal congestion, runny nose, watery eyes, hacking cough and sometimes fever. It is a viral infection, so things like antibiotics, which are often mistakenly prescribed for colds, won't help. Giving antibiotics for viral diseases is a distressingly common practice. Studies have shown that 60 percent of patients who went to the doctor with one of the viruses that cause the common cold received an inappropriate prescription for antibiotics.
Sales of cold and flu formulas slipped slightly between 2009 and 2010, down 1.2% for sales of $3.8 billion. Helping to decelerate the losses was both competitive threats from alternative remedies and increased sales of private label products across all segments of the market, as consumers sought out more affordable remedies during the poor economy, often with the view that these medicines work just as well as national brands. However, most of these products simply mask the symptoms and do little or nothing to address attacking the cause. Many people have lost confidence in OTC products due to bad press, a number of recalls and FDA recommendations. Further, on March 2, 2011 the FDA announced steps to remove more than 500 prescription cold, cough, and allergy products from the market because of potential safety concerns. The FDA asked companies to stop manufacturing the 500 products within 90 days and stop shipping them within 180 days. Some manufacturers were required to stop making and shipping their products immediately.
Robert deZanger, CEO of Natures Bioceuticals stated, "Although the Cold and Flu market is flooded with a number of established brands, we are confident that we can capture a significant portion of the market with an all natural product that really works. The company has the potential to capture 3% of the US market within a 3 year period, which would potentially generate over $100,000,000 in revenues for the company. Our formula contains over twenty different herbs that are all 'active ingredients.' The formula provides relief from the cold and flu symptoms, but more importantly, it boosts the body's immune response to combat the cause of the virus. When taken at the onset of symptoms the formula has shown the ability to reduce the severity and duration of a cold or flu. It has also in many cases arrested the virus before symptoms are able to come to fruition. The inventor has for many years been conducting research to find a 'cure' for the common cold. This formula was invented as a result of that ongoing research. Upon closing of the purchase we intend to hire an independent testing group to do a clinical trial(s) to formally document the results we have achieved and publish a report for the medical community."
About Nature's Bioceuticals:
Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.
Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA."
In addition to historical information, this release contains forward-looking statements. Mistral Ventures Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Mistral Ventures Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.
Media Contact:
Robert Dezanger
Phone Number: 561-200-7300
E-mail: info@naturesbioceutacles.com
www.naturesbioceuticals.com
SOURCE Mistral Ventures Inc.
News 
Market Data 
Discover 
